Efficacy and safety of Abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non–small cell lung cancer, and other solid tumors

Cancer Discovery

Volumn 6, Issue 7, 2016, Pages 740-753

  Patnaik, Amita ^a   Rosen, Lee S ^b   Tolaney, Sara M ^c   Tolcher, Anthony W ^a   Goldman, Jonathan W ^b   Gandhi, Leena ^c   Papadopoulos, Kyriakos P ^a   Beeram, Muralidhar ^a   Rasco, Drew W ^a   Hilton, John F ^c,f   Nasir, Aejaz ^d   Beckmann, Richard P ^d   Schade, Andrew E ^d   Fulford, Angie D ^d   Nguyen, Tuan S ^d   Martinez, Ricardo ^d   Kulanthaivel, Palaniappan ^d   Li, Lily Q ^d   Frenzel, Martin ^d   Cronier, Damien M ^d   Chan, Edward M ^d   Flaherty, Keith T ^e   Wen, Patrick Y ^c   Shapiro, Geoffrey I ^c   more..

^a South Texas Accelerated Research Therapeutics   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABEMACICLIB; CYCLIN DEPENDENT KINASE 4; DNA TOPOISOMERASE (ATP HYDROLYSING); FULVESTRANT; 5-(4-ETHYLPIPERAZIN-1-YLMETHYL)PYRIDIN-2-YL)-(5-FLUORO-4-(7-FLUORO-3-ISOPROPYL-2-METHYL-3H-BENZIMIDAZOL-5-YL)PYRIMIDIN-2-YL)AMINE; AMINOPYRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; CYCLIN DEPENDENT KINASE 6;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ARTICLE; BREAST CANCER; CELL CYCLE PROGRESSION; CEREBROSPINAL FLUID ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ELIMINATION HALF-LIFE; FATIGUE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MOUSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PROTEIN EXPRESSION; SKIN BIOPSY; TANDEM MASS SPECTROMETRY; THROMBOCYTOPENIA; TUMOR VOLUME; VOMITING; WEIGHT REDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE MODEL; DRUG MONITORING; DRUG SCREENING; FEMALE; LUNG NEOPLASMS; MALE; METASTASIS; MOLECULARLY TARGETED THERAPY; MORTALITY; NEOPLASMS; TREATMENT OUTCOME; X-RAY COMPUTED TOMOGRAPHY;

AMINOPYRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; DISEASE MODELS, ANIMAL; DRUG MONITORING; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICE; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84977598561     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-16-0095     Document Type: Article

References (47)

1. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323–30.
2. Morgan DO. Principles of CDK regulation. Nature 1995; 374: 131–4.
3. Carnero A, Hannon GJ. The INK4 family of CDK inhibitors. Curr Top Microbiol Immunol 1998; 227: 43–55.
4. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501–12.
5. Sherr CJ, Beach D, Shapiro GI. Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov 2016; 6: 1–15.
6. Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and CDK inhibitors in human cancer. Adv Cancer Res 1996; 68: 67–108.
7. Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672–7.
8. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006; 24: 1770–83.
9. Anders L, Ke N, Hydbring P, Choi YJ, Widlund HR, Chick JM, et al. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell 2011; 20: 620–34.
10. Zou X, Ray D, Aziyu A, Christov K, Boiko AD, Gudkov AV, et al. CDK4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence. Genes Dev 2002; 16: 2923–34.
11. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001; 411: 1017–21.
12. Reddy HK, Mettus RV, Rane SG, Grana X, Litvin J, Reddy EP. Cyclindependent kinase 4 expression is essential for neu-induced breast tumorigenesis. Cancer Res 2005; 65: 10174–8.
13. Yu Q, Sicinska E, Geng Y, Ahnstrom M, Zagozdzon A, Kong Y, et al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell 2006; 9: 23–32.
14. Puyol M, Martin A, Dubus P, Mulero F, Pizcueta P, Khan G, et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 2010; 18: 63–73.
15. Choi YJ, Li X, Hydbring P, Sanda T, Stefano J, Christie AL, et al. The requirement for cyclin D function in tumor maintenance. Cancer Cell 2012; 22: 438–51.
16. Serrano M, Gomez-Lahoz E, DePinho RA, Beach D, Bar-Sagi D. Inhibition of ras-induced proliferation and cellular transformation by p16INK4. Science 1995; 267: 249–52.
17. Malumbres M, Sotillo R, Santamaria D, Galan J, Cerezo A, Ortega S, et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 2004; 118: 493–504.
18. Kozar K, Ciemerych MA, Rebel VI, Shigematsu H, Zagozdzon A, Sicinska E, et al. Mouse development and cell proliferation in the absence of D-cyclins. Cell 2004; 118: 477–91.
19. Sherr CJ, Roberts JM. Living with or without cyclins and cyclindependent kinases. Genes Dev 2004; 18: 2699–711.
20. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009; 9: 153–66.
21. Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del PM, Lallena MJ, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/ in combination with gemcitabine. Invest New Drugs 2014; 32: 825–37.
22. Tate SC, Cai S, Ajamie RT, Burke T, Beckmann RP, Chan EM, et al. Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts. Clin Cancer Res 2014; 20: 3763–74.
23. Yadav V, Burke TF, Huber L, Van Horn RD, Zhang Y, Buchanan SG, et al. The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation. Mol Cancer Ther 2014; 13: 2253–63.
24. Raub TJ, Wishart GN, Kulanthaivel P, Staton BA, Ajamie RT, Sawada GA, et al. Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with temozolomide in an intracranial glioblastoma xenograft. Drug Metab Dispos 2015; 43: 1360–71.
25. Caldon CE, Daly RJ, Sutherland RL, Musgrove EA. Cell cycle control in breast cancer cells. J Cell Biochem 2006; 97: 261–74.
26. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009; 11: R77.
27. Van Allen EM, Wagle N, Stojanov P, Perrin DL, Cibulskis K, Marlow S, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med 2014; 20: 682–8.
28. Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profi les, and therapeutic vulnerabilities. Cancer Discov 2015; 5: 860–77.
29. Nam EJ, Kim YT. Alteration of cell-cycle regulation in epithelial ovarian cancer. Int J Gynecol Cancer 2008; 18: 1169–82.
30. Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, et al. Defi nitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 2011; 21: 419–23.
31. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defi nes human glioblastoma genes and core pathways. Nature 2008; 455: 1061–8.
32. Dai CY, Furth EE, Mick R, Koh J, Takayama T, Niitsu Y, et al. p16(INK4a) expression begins early in human colon neoplasia and correlates inversely with markers of cell proliferation. Gastroenterology 2000; 119: 929–42.
33. Sheppard KE, McArthur GA. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. Clin Cancer Res 2013; 19: 5320–8.
34. Schwartz GK, LoRusso PM, Dickson MA, Randolph SS, Shaik MN, Wilner KD, et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer 2011; 104: 1862–8.
35. Flaherty KT, LoRusso PM, Demichele A, Abramson VG, Courtney R, Randolph SS, et al. Phase I, dose-escalation trial of the oral cyclindependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res 2012; 18: 568–76.
36. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015; 16: 25–35.
37. Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 2015; 373: 209–19.
38. Kim S, Loo A, Chopra R, Caponigro G, Huang A, Vora S, et al. LEE011: an orally bioavailable, selective small molecule inhibitor of CDK4/6 reactivating Rb in cancer. Mol Cancer Ther 12[11S:PRO2]. 2013.
39. Infante JR, Shapiro GI, Witteveen P, Gerecitano JF, Ribrag V, Chugh R. Phase 1 multicenter, open label, dose-escalation study of LEE011, an oral inhibitor of cyclin-dependent kinase 4/6, in patients with advanced solid tumors or lymphomas. Mol Cancer Ther 2013; 12 (11 suppl; abstr A276).
40. Guan JL, Zhong WZ, An SJ, Yang JJ, Su J, Chen ZH, et al. KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy. Ann Surg Oncol 2013; 20: 1381–8.
41. Calles A, Sholl LM, Rodig SJ, Pelton AK, Hornick JL, Butaney M, et al. Immunohistochemical loss of LKB1 is a biomarker for more aggressive biology in KRAS-mutant lung adenocarcinoma. Clin Cancer Res 2015; 21: 2851–60.
42. Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T, et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012; 483: 613–7.
43. DeMichele A, Clark AS, Tan KS, Heitjan DF, Gramlich K, Gallagher M, et al. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb + advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin Cancer Res 2015; 21: 995–1001.
44. Sharpless NE, Sherr CJ. Forging a signature of in vivo senescence. Nat Rev Cancer 2015; 15: 397–408.
45. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228–47.
46. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–81.
47. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 fi eld. Nat Rev Cancer 2009;9:701–13.